Effect of hemodialysis on plasma levels of vasoactive peptides: endothelin, calcitonin gene-related peptide and human atrial natriuretic peptide.
To determine the role of vasoactive peptides such as endothelin (ET), calcitonin gene-related peptide (CGRP) and human atrial natriuretic peptide (hANP) in the regulation of blood pressure in uremic patients, and to determine the effect of various types of dialyzer membranes on hemodialysis (HD)-induced changes in plasma levels of such peptides, plasma ET, CGRP and hANP were measured in HD patients and patients on continuous ambulatory peritoneal dialysis (CAPD). Plasma levels of ET, CGRP, and hANP were significantly higher in HD and CAPD patients than in healthy subjects. There were no significant differences in plasma levels of ET, CGRP, and hANP between hypertensive and normotensive HD patients, and no significant correlation was observed between HD-induced changes in plasma levels and changes in blood pressure. Plasma levels of ET decreased when HD was performed using high-flux membranes, such as polyacrylonitrile (PAN), polymethyl methacrylate (PMMA) and cellulose triacetate (CTA), but did not decrease using a saponified cellulose (SC) membrane. Plasma levels of CGRP decreased in the case of PAN, but increased significantly with PMMA and showed no change with SC and CTA. Plasma levels of hANP decreased in all types of dialyzer membranes due to decreased secretion. These results indicate that the effect of HD on plasma levels of ET and CGRP, but not hANP, depends on the type of dialyzer membrane used.
Niwa
T
T
Department of Internal Medicine, Nagoya University Branch Hospital, Japan.
Fujishiro
T
T
Uema
K
K
Tsuzuki
T
T
Tominaga
Y
Y
Emoto
Y
Y
Miyazaki
T
T
Maeda
K
K
D009320:Atrial Natriuretic Factor / Q000097:blood*; D015740:Calcitonin Gene-Related Peptide / Q000097:blood*; D016232:Endothelins / Q000097:blood*; D005260:Female; D006801:Humans; D007022:Hypotension / Q000209:etiology; D007688:Kidneys, Artificial / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D006435:Renal Dialysis / Q000009:adverse effects; D014511:Uremia / Q000097:blood / Q000628:therapy
D016232:Endothelins; D009320:Atrial Natriuretic Factor; D015740:Calcitonin Gene-Related Peptide